tetano
Editor, Senior Moderator
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection
Benjamin Petsch,
Margit Schnee,
Annette B Vogel,
Elke Lange,
Bernd Hoffmann,
Daniel Voss,
Thomas Schlake,
Andreas Thess,
Karl-Josef Kallen,
Lothar Stitz
& Thomas Kramps
Affiliations
Contributions
Corresponding authors
Nature Biotechnology
(2012)
doi:10.1038/nbt.2436
Received
02 July 2012
Accepted
25 October 2012
Published online
25 November 2012
Article tools
Full text
PDF
Citation
Reprints
Rights & permissions
Metrics
Abstract
Abstract
Accession codes
Author information
Supplementary information
Despite substantial improvements, influenza vaccine production?and availability?remain suboptimal. Influenza vaccines based on mRNA may offer a solution as sequence-matched, clinical-grade material could be produced reliably and rapidly in a scalable process, allowing quick response to the emergence of pandemic strains. Here we show that mRNA vaccines induce balanced, long-lived and protective immunity to influenza A virus infections in even very young and very old mice and that the vaccine remains protective upon thermal stress. This vaccine format elicits B and T cell?dependent protection and targets multiple antigens, including the highly conserved viral nucleoprotein, indicating its usefulness as a cross-protective vaccine. In ferrets and pigs, mRNA vaccines induce immunological correlates of protection and protective effects similar to those of a licensed influenza vaccine in pigs. Thus, mRNA vaccines could address substantial medical need in the area of influenza prophylaxis and the broader realm of anti-infective vaccinology.
http://www.nature.com/nbt/journal/vaop/ncurrent/abs/nbt.2436.html
Benjamin Petsch,
Margit Schnee,
Annette B Vogel,
Elke Lange,
Bernd Hoffmann,
Daniel Voss,
Thomas Schlake,
Andreas Thess,
Karl-Josef Kallen,
Lothar Stitz
& Thomas Kramps
Affiliations
Contributions
Corresponding authors
Nature Biotechnology
(2012)
doi:10.1038/nbt.2436
Received
02 July 2012
Accepted
25 October 2012
Published online
25 November 2012
Article tools
Full text
Citation
Reprints
Rights & permissions
Metrics
Abstract
Abstract
Accession codes
Author information
Supplementary information
Despite substantial improvements, influenza vaccine production?and availability?remain suboptimal. Influenza vaccines based on mRNA may offer a solution as sequence-matched, clinical-grade material could be produced reliably and rapidly in a scalable process, allowing quick response to the emergence of pandemic strains. Here we show that mRNA vaccines induce balanced, long-lived and protective immunity to influenza A virus infections in even very young and very old mice and that the vaccine remains protective upon thermal stress. This vaccine format elicits B and T cell?dependent protection and targets multiple antigens, including the highly conserved viral nucleoprotein, indicating its usefulness as a cross-protective vaccine. In ferrets and pigs, mRNA vaccines induce immunological correlates of protection and protective effects similar to those of a licensed influenza vaccine in pigs. Thus, mRNA vaccines could address substantial medical need in the area of influenza prophylaxis and the broader realm of anti-infective vaccinology.
http://www.nature.com/nbt/journal/vaop/ncurrent/abs/nbt.2436.html